Ionis Pharma Insider Eugene Schneider Reports Ownership Change

TL;DR

**Ionis Pharma insider Eugene Schneider just updated his ownership report.**

AI Summary

This Form 4 filing indicates that Eugene Schneider, an insider at Ionis Pharmaceuticals Inc., reported a change in beneficial ownership of securities. While the filing itself doesn't detail specific transactions like buys or sells, it signals that an insider's holdings have been updated as of the report period ending March 19, 2026. This matters to investors because insider activity can sometimes signal management's confidence (or lack thereof) in the company's future prospects, although this particular filing is merely a notification of a change rather than a specific transaction.

Why It Matters

Insider ownership changes can offer clues about a company's health and future, as those closest to the business adjust their stakes.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of an insider's ownership change and does not inherently indicate a high risk.

Analyst Insight

A smart investor would note this routine filing but await further details on specific transactions (buys or sells) by Eugene Schneider before making any investment decisions based solely on this information.

Key Players & Entities

• Schneider Eugene (person) — Reporting Owner
• IONIS PHARMACEUTICALS INC (company) — Issuer

FAQ

Key Financial Figures

• $70.76 — ple transactions at prices ranging from $70.76 to $71.375 inclusive. The reporting per
• $71.375 — ctions at prices ranging from $70.76 to $71.375 inclusive. The reporting person underta

Filing Documents

• primary_doc.html (4)
• primary_doc.xml (4) — 4KB
• 0000874015-26-000152.txt ( ) — 5KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Schneider Eugene (Last) (First) (Middle) C/O IONIS PHARMACEUTICALS 2855 GAZELLE CT (Street) CARLSBAD CALIFORNIA 92010 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [ IONS ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) EVP, Chf Clinical Develop Ofcr 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/19/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/19/2026 S 5,812 (1) D $ 70.9715 (2) 63,890 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025. 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.76 to $71.375 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission,upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider 03/23/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR